Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression

Antiviral Research

Volumn 107, Issue 1, 2014, Pages 42-49

  Beliakova Bethell, Nadejda ^a   Jain, Sonia ^a   Woelk, Christopher H ^a,b,c   Witt, Mallory D ^d   Sun, Xiaoying ^a   Lada, Steven M ^b   Spina, Celsa A ^a,b   Goicoechea, Miguel ^e   Rought, Steffney E ^b   Haubrich, Richard ^a   Dubé, Michael P ^f  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SCRIPPS CLINIC   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

CCR5 inhibitors; Gene expression; HIV; Maraviroc

Indexed keywords

ATAZANAVIR; BILIRUBIN; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD4 T LYMPHOCYTE RECOVERY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CLINICAL ARTICLE; CLINICAL TRIAL; DOWN REGULATION; DRUG DOSE INTENSIFICATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MALE; MENTAL HEALTH; MICROARRAY ANALYSIS; OPEN STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RNA ISOLATION; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; AGED; BIOSYNTHESIS; CELL PROLIFERATION; HIV INFECTIONS; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYCLOHEXANES; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIV INFECTIONS; HUMANS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; TREATMENT OUTCOME; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; VIREMIA;

EID: 84900477263     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.04.005     Document Type: Article

References (28)

1. N. Beliakova-Bethell, M. Massanella, C. White, S.M. Lada, P. Du, F. Vaida, J. Blanco, C.A. Spina, and C.H. Woelk The effect of cell subset isolation method on gene expression in leukocytes Cytometry A 85A 2014 94 104
2. D.A. Cooper, J. Heera, J. Goodrich, M. Tawadrous, M. Saag, E. DeJesus, N. Clumeck, S. Walmsley, N. Ting, E. Coakley, J.D. Reeves, G. Reyes-Teran, M. Westby, E. Van Der Ryst, P. Ive, L. Mohapi, H. Mingrone, A. Horban, F. Hackman, J. Sullivan, and H. Mayer Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection J. Infect. Dis. 201 2010 803 813
3. P. Corbeau, and J. Reynes CCR5 antagonism in HIV infection: ways, effects, and side effects AIDS 23 2009 1931 1943
4. F. Cossarini, A. Galli, L. Galli, A. Bigoloni, S. Salpietro, C. Vinci, L. Della Torre, N. Gianotti, V. Spagnuolo, A. Lazzarin, A. Castagna, and S. Nozza Immune recovery and T cell subset analysis during effective treatment with maraviroc J. Antimicrob. Chemother. 67 2012 2474 2478
5. L. Cuzin, S. Trabelsi, P. Delobel, C. Barbuat, J. Reynes, C. Allavena, G. Peytavin, J. Ghosn, C. Lascoux-Combe, C. Psomas, P. Corbeau, and P. Flandre Maraviroc intensification of stable antiviral therapy in HIV-1-infected patients with poor immune restoration: MARIMUNO-ANRS 145 study JAIDS 61 2012 557 564
6. P. Dorr, M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 49 2005 4721 4732
7. F. Dronda, S. Moreno, A. Moreno, J.L. Casado, M.J. Perez-Elias, and A. Antela Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression Clin. Infect. Dis. 35 2002 1005 1009
8. J. Ernst, and Z. Bar-Joseph STEM: a tool for the analysis of short time series gene expression data BMC Bioinformatics 7 2006 191
9. E. Florence, J. Lundgren, C. Dreezen, M. Fisher, O. Kirk, A. Blaxhult, G. Panos, C. Katlama, S. Vella, and A. Phillips Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study HIV Med. 4 2003 255 262
10. M. Goicoechea, D.M. Smith, L. Liu, S. May, A.R. Tenorio, C.C. Ignacio, A. Landay, and R. Haubrich Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA J. Infect. Dis. 194 2006 29 37
11. S. Grabar, V. Le Moing, C. Goujard, C. Leport, M.D. Kazatchkine, D. Costagliola, and L. Weiss Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy Ann. Intern. Med. 133 2000 401 410
12. D.W. Haas, D.E. Geraghty, J. Andersen, J. Mar, A.A. Motsinger, R.T. D'Aquila, D. Unutmaz, C.A. Benson, M.D. Ritchie, and A. Landay Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS clinical trials group study J. Infect. Dis. 194 2006 1098 1107
13. G. Herbein, and K.A. Khan Is HIV infection a TNF receptor signalling-driven disease? Trends Immunol. 29 2008 61 67
14. P.W. Hunt, N.S. Shulman, T.L. Hayes, V. Dahl, M. Somsouk, N.T. Funderburg, B. McLaughlin, A.L. Landay, O. Adeyemi, L.E. Gilman, B. Clagett, B. Rodriguez, J.N. Martin, T.W. Schacker, B.L. Shacklett, S. Palmer, M.M. Lederman, and S.G. Deeks The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial Blood 121 2013 4635 4646
15. M. Imbeault, K. Giguere, M. Ouellet, and M.J. Tremblay Exon level transcriptomic profiling of HIV-1 infected CD4+ T cells reveals virus-induced genes and host environment favorable for viral replication PLoS Pathog. 8 2012 e1002861
16. W.E. Johnson, C. Li, and A. Rabinovic Adjusting batch effects in microarray expression data using empirical Bayes methods Biostatistics 8 2007 118 127
17. G.R. Kaufmann, L. Perrin, G. Pantaleo, M. Opravil, H. Furrer, A. Telenti, B. Hirschel, B. Ledergerber, P. Vernazza, E. Bernasconi, M. Rickenbach, M. Egger, and M. Battegay CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the swiss HIV cohort study Arch. Intern. Med. 163 2003 2187 2195
18. Q. Li, T. Schacker, J. Carlis, G. Beilman, P. Nguyen, and A.T. Haase Functional genomic analysis of the response of HIV-1-infected lymphatic tissue to antiretroviral therapy J. Infect. Dis. 189 2004 572 582
19. G. Marchetti, A. Gori, A. Casabianca, M. Magnani, F. Franzetti, M. Clerici, C.-F. Perno, A.d.A. Monforte, M. Galli, and L Meroni Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART AIDS 20 2006 1727 1736
20. M. Massanella, A. Singhania, N. Beliakova-Bethell, R. Pier, S.M. Lada, C.H. White, J. Pérez-Santiago, J. Blanco, D.D. Richman, S.J. Little, and C.H. Woelk Differential gene expression in HIV-infected individuals following ART Antiviral Res. 100 2013 420 428
21. R Developmental Core Team R: A Language and Environment for Statistical Computing 2011 R Foundation of Statistical Computing Vienna, Austria
22. R. Rossi, M. Lichtner, A. De Rosa, I. Sauzullo, F. Mengoni, A.P. Massetti, C.M. Mastroianni, and V. Vullo In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells Clin. Exp. Immunol. 166 2011 184 190
23. S. Rusconi, P. Vitiello, F. Adorni, E. Colella, E. Focà, A. Capetti, P. Meraviglia, C. Abeli, S. Bonora, M. D'Annunzio, A.D. Biagio, M. Di Pietro, L. Butini, G. Orofino, M. Colafigli, G. d'Ettorre, D. Francisci, G. Parruti, A. Soria, A.R. Buonomini, C. Tommasi, S. Mosti, F. Bai, S. Di Nardo Stuppino, M. Morosi, M. Montano, P. Tau, E. Merlini, and G. Marchetti Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial PLoS One 8 2013 e80157
24. M. Saag, J. Goodrich, G. Fätkenheuer, B. Clotet, N. Clumeck, J. Sullivan, M. Westby, E. van der Ryst, H. Mayer A4001029 Study Group A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1 J. Infect. Dis. 199 2009 1638 1647
25. J. Saison, T. Ferry, J. Demaret, D. Maucort Boulch, F. Venet, T. Perpoint, F. Ader, V. Icard, C. Chidiac, G. Monneret Lyon HIV Cohort Study Association between discordant immunological response to HAART, regulatory T cells percentage, immune cell activation and very low level viremia in HIV-infected patients Clin. Exp. Immunol. 2014 10.1111/cei.12278
26. L. Seu, G.M. Ortiz, L. Epling, E. Sinclair, L.A. Swainson, U.D. Bajpai, Y. Huang, S.G. Deeks, P.W. Hunt, J.N. Martin, and J.M. McCune Higher CD27+CD8+ T cells percentages during suppressive antiretroviral therapy predict greater subsequent CD4+ T cell recovery in treated HIV infection PLoS One 8 2013 e84091
27. R. Simon, A. Lam, M.C. Li, M. Ngan, S. Menenzes, and Y. Zhao Analysis of gene expression data using BRB-array tools Cancer Inform. 3 2007 11 17
28. T.J. Wilkin, C.M. Lalama, J. McKinnon, R.T. Gandhi, N. Lin, A. Landay, H. Ribaudo, L. Fox, J.S. Currier, J.W. Mellors, R. Gulick, and A.R. Tenorio A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256 J. Infect. Dis. 206 2012 534 542